"The process is moving ahead according to schedule," Vince Forlenza, president of BD Biosciences, said at the JPMorgan Healthcare Conference, held here this week.
As GenomeWeb News reported last October, BD said it plans to sell the Clontech business because it wants to "focus its strategy on cell analysis, discovery labware and its new platforms of imaging and in vitro drug metabolism/toxicity testing," Edward Ludwig, chairman, president and CEO of BD said in a statement.
The planned sale "also allows us to direct our resources toward higher-growth opportunities in the pharmaceutical drug discovery arena," Ludwig added. BD has still not disclosed the buyer.
BD has hired Goldman Sachs to be its financial advisor for the divestiture.